International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis (INTERTB)

Seminar to discuss strategies for improving the current treatment of tuberculosis in order to be able to meet the Millennium Development Goals for the Global Eradication of Tuberculosis.
St. George’s, University of London, Thursday March 22\textsuperscript{nd}, 2007

DRAFT AGENDA

First morning session: Introduction: Chair Baroness Elaine Murphy

09h00 – 09h10 Welcome and introductions
Baroness Elaine Murphy

09h10 – 09h20 Tuberculosis: the problem
Dr Katherine Floyd

09h20 – 09h30 Treating tuberculosis: Old and New drugs
Prof Denis Mitchison

09h30 – 09h45 The Challenges of Phase III Trials
Prof Andrew Nunn

09h45 – 10h00 Competition in development
Dr Tom Harrison

10h00 – 10h15 Discussion

10h15 - 10h35 Coffee break

Second morning session: The UK effort: Chair Prof. George Griffin

10h35 – 10h45 Fluoroquinolones: the Oflotub Trial
Prof Denis Mitchison

10h45 – 11h00 Fluoroquinolones: the Remox Trial
Prof Stephen Gillespie

11h00 – 11h20 Rifamycins: The Rifaquin Trial
Dr Amina Jindani

11h20 – 11h40 Rifamycins: Trials with rifabutin
Dr Bertel Squire

11h40 - 12h00 HIV/TB Drug interactions
Dr Saye Khoo

12h00 - 12h15 The role of NGOs
Dr Phillippe Guérin

12h15 – 13h00 Discussion

13h00 – 14h00 pm LUNCH

Afternoon session: Novel strategies: Chair Prof. Anthony Coates

14h00 - 14h10 Introductory remarks
Prof Anthony Coates

14h10 – 14h30 Modelling and novel phase II designs
Dr Geraint Davies

14h30 – 14h45 The transition to shortening treatment
Prof Denis Mitchison

14h45 – 15h00 Novel strategies for assessing rifamycin resistance
and treatment response
Dr Carlton Evans

15h00 – 15h15 Discussion: What to do now
Moderator Dr Tom Harrison

15h15 - 15h30 Discussion: What to do in the future
Moderator Prof Denis Mitchison

agenda.doc